{"id":391440,"date":"2015-03-17T00:00:00","date_gmt":"2015-03-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbasim0215-biopharma-chronic-obstructive-pulmonary-disease-decision-base-us-2015\/"},"modified":"2026-04-18T11:44:16","modified_gmt":"2026-04-18T11:44:16","slug":"dbasim0215-biopharma-chronic-obstructive-pulmonary-disease-decision-base-us-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbasim0215-biopharma-chronic-obstructive-pulmonary-disease-decision-base-us-2015\/","title":{"rendered":"Chronic Obstructive Pulmonary Disease | Decision Base | US | 2015"},"content":{"rendered":"<p><em>How Can Novel LABA\/LAMA Combinations Differentiate Themselves in an Increasingly Crowded Market?<\/em><\/p>\n<p>Treatment of chronic obstructive pulmonary disease (COPD) is dominated by bronchodilators, and polypharmacy is commonplace as patients\u2019 COPD worsens. Although substantial opportunity exists for a disease-modifying therapy, development of new COPD therapies has focused instead on therapies that combine two bronchodilators in one inhaler. As the COPD marketplace becomes increasingly crowded with these fixed-dose combinations, emerging therapies will need to be clearly differentiated from competitors to experience substantial uptake.<\/p>\n","protected":false},"template":"","class_list":["post-391440","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-obstructive-pulmonary-disease","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391440\/revisions"}],"predecessor-version":[{"id":394563,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391440\/revisions\/394563"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}